{
  "paper_id": "82722b89a6c49087f09c56d5d6b58e2bfe33bc7e",
  "metadata": {
    "title": "Use of the Fluocinolone Acetonide Intravitreal Implant for the Treatment of Noninfectious Posterior Uveitis: 3-Year Results of a Randomized Clinical Trial in a Predominantly Asian Population",
    "coda_data_split": "train",
    "coda_paper_id": 3517,
    "coda_has_expert_labels": false,
    "subset": "custom_license"
  },
  "abstract": [
    {
      "original_text": "Introduction: The fluocinolone acetonide (FA) intravitreal implant 0.59 mg (Retisert Ò , Bausch ? Lomb, Rochester, NY, USA) provides sustained release of FA directly to the vitreous cavity over a prolonged period of time. The purpose of this study was to evaluate the safety and efficacy of a 0.59-and 2.1-mg FA",
      "sentences": [
        [
          {
            "segment_text": "Introduction : The fluocinolone acetonide ( FA ) intravitreal implant 0.59 mg ( Retisert Ò , Bausch ?",
            "crowd_label": "background"
          }
        ],
        [
          {
            "segment_text": "Lomb , Rochester , NY ,",
            "crowd_label": "other"
          },
          {
            "segment_text": "USA ) provides sustained release of FA directly to the vitreous cavity over a prolonged period of time .",
            "crowd_label": "background"
          }
        ],
        [
          {
            "segment_text": "The purpose of this study was to evaluate the safety and efficacy of a 0.59-and 2.1-mg FA",
            "crowd_label": "purpose"
          }
        ]
      ]
    }
  ],
  "abstract_stats": {
    "paragraph_num": "1",
    "sentence_num": "3",
    "segment_num": "4",
    "token_num": "60"
  }
}